Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic • Triple-negative breast cancer
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
Does the metaplastic histology influence your decision-making?
Answer from: Medical Oncologist at Community Practice
For a patient with triple-negative metaplastic breast cancer and microinvasive residual disease (ypT1miN0)following neoadjuvant therapy, the decision to use adjuvant capecitabine is nuanced and not definitively addressed in current guidelines or trials.General TNBC with Residual Disease:Multipl...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
Short answer: yes. Although we have data from CREATE-X, data from GEICAM were negative. Data from FinXX and SYSUCC001, however, were positive. TNBC still carries a high risk of recurrence even with small-volume residual disease. Retrospective and prospective data suggest that chemotherapy is particu...